Sevelamer carbonate Winthrop 800 mg
Non-calcium phosphate binder for hyperphosphatemia in chronic kidney disease
Quick Facts About Sevelamer carbonate Winthrop
Key Takeaways About Sevelamer carbonate Winthrop
- Non-absorbed polymer: Sevelamer stays in the gut and is excreted in the feces — it does not enter the bloodstream
- No calcium, no aluminium, no metal: Unlike older phosphate binders, sevelamer does not raise calcium or add metal load
- Take with meals: Sevelamer must be taken with food to bind dietary phosphate effectively
- Also lowers LDL cholesterol: Sevelamer binds bile acids, producing modest LDL-C reduction as a clinical bonus
- Timing matters for other drugs: Separate doses of sevelamer from interacting drugs (levothyroxine, ciprofloxacin, immunosuppressants) by several hours
What Is Sevelamer carbonate Winthrop and What Is It Used For?
Sevelamer carbonate Winthrop is a phosphate-binding medicine used in adults with chronic kidney disease to lower high blood phosphate levels. It is taken by mouth with meals and works inside the intestines to trap phosphate from food before it can be absorbed into the bloodstream.
Sevelamer carbonate Winthrop 800 mg is a generic, film-coated tablet containing the active substance sevelamer carbonate. It is manufactured by Zentiva (previously Sanofi Winthrop Industrie) and authorised across the European Union following the reference medicine sevelamer carbonate (Renvela). It belongs to a class of medicines known as phosphate binders, and more specifically to the subgroup of non-calcium, non-metallic, non-absorbed polymer binders.
The medicine is classified under the Anatomical Therapeutic Chemical (ATC) code V03AE02, which groups medicines used in the treatment of hyperkalemia and hyperphosphatemia. Sevelamer carbonate is specifically indicated for the control of hyperphosphatemia (elevated phosphate in the blood) in two well-defined groups of patients:
- Adults receiving dialysis — both hemodialysis and peritoneal dialysis, where the kidneys can no longer remove phosphate efficiently
- Adults with chronic kidney disease not on dialysis who have a serum phosphate concentration of 1.78 mmol/L (5.5 mg/dL) or higher
Sevelamer carbonate Winthrop should always be used as part of a broader treatment plan that may include dietary phosphate restriction, calcium and vitamin D management, and treatment of secondary hyperparathyroidism, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.
Why Controlling Phosphate Is Important in Kidney Disease
In healthy adults, the kidneys tightly regulate serum phosphate by excreting excess phosphate in the urine. When kidney function declines — typically at a glomerular filtration rate (GFR) below 30 mL/min/1.73 m² — phosphate accumulates in the blood. Hyperphosphatemia is a central driver of CKD-Mineral and Bone Disorder (CKD-MBD), a syndrome that contributes to:
- Secondary hyperparathyroidism due to reduced calcitriol production and chronic parathyroid stimulation
- Renal osteodystrophy, a bone disease characterised by weakness, pain, and fractures
- Vascular and soft tissue calcification, strongly associated with cardiovascular mortality in dialysis patients
- Calciphylaxis, a rare but often fatal condition of calcium deposition in small blood vessels
Several large observational studies, including those from the Dialysis Outcomes and Practice Patterns Study (DOPPS), have linked elevated serum phosphate to higher all-cause and cardiovascular mortality in dialysis patients. KDIGO guidelines therefore recommend lowering elevated phosphate levels toward the normal range while avoiding hypercalcemia.
How Sevelamer Carbonate Works
Sevelamer carbonate is a cross-linked polyallylamine polymer that is not absorbed from the gastrointestinal tract. When the tablet is ingested with a meal, the polymer swells in the stomach and small intestine and presents multiple positively charged amine groups along its backbone. These amines bind dietary phosphate anions through ionic interactions and hydrogen bonding, forming an insoluble complex that cannot cross the intestinal wall.
The bound phosphate is then eliminated from the body in the stool. By reducing the amount of phosphate that enters the bloodstream, sevelamer gradually lowers serum phosphate levels. Because the polymer is not absorbed, there is no risk of systemic accumulation, and sevelamer does not contribute any calcium, aluminium, lanthanum, or iron to the body — an important advantage compared with older phosphate binders.
Additional Metabolic Effects
Clinical studies have shown that sevelamer also binds bile acids in the small intestine. This secondary effect interrupts the enterohepatic circulation of bile acids and results in a modest but consistent reduction in LDL cholesterol and total cholesterol. Unlike calcium-based phosphate binders, sevelamer does not increase serum calcium and may reduce the progression of coronary artery and aortic calcification in dialysis patients, as demonstrated in the Treat-to-Goal and Renagel In New Dialysis (RIND) studies.
"Sevelamer carbonate Winthrop" is the European marketing name for a generic sevelamer carbonate product. Other brand names containing the same active substance include Renvela (the originator). All products with the active ingredient sevelamer carbonate are considered bioequivalent and have the same indication.
What Should You Know Before Taking Sevelamer carbonate Winthrop?
Do not take Sevelamer carbonate Winthrop if you have low phosphate in your blood (hypophosphatemia), a bowel obstruction, or a hypersensitivity to sevelamer or any excipient. Tell your doctor about any swallowing, digestive, or bowel disorders, and about every other medicine you take, because sevelamer can affect the absorption of many drugs.
Sevelamer carbonate is generally well tolerated, but there are several situations where it must not be used or where it requires close medical supervision. A thorough pretreatment evaluation by your nephrologist will determine whether this phosphate binder is appropriate for you.
Contraindications
You must not take Sevelamer carbonate Winthrop if:
- You have low blood phosphate levels (hypophosphatemia) — sevelamer would lower phosphate even further
- You have a bowel obstruction — sevelamer may worsen obstruction and cause bowel perforation
- You are hypersensitive (allergic) to sevelamer or to any of the excipients (inactive ingredients) listed in the product information
Warnings and Precautions
Talk to your doctor, pharmacist, or nurse before taking Sevelamer carbonate Winthrop if any of the following apply:
- Swallowing difficulties (dysphagia) — sevelamer tablets are large and must be swallowed whole; patients with swallowing problems may need the powder formulation of the reference product
- Severe gastrointestinal motility disorders, including gastroparesis, retained gastric contents, and abnormal or irregular bowel movements
- Active inflammatory bowel disease (IBD) or a history of major gastrointestinal surgery
- History of bowel obstruction, ileus, diverticulosis, or gastrointestinal bleeding — cases of serious obstruction, perforation, and bleeding have been reported in post-marketing surveillance
- Metabolic acidosis — although sevelamer carbonate may have a modest buffering effect, serum bicarbonate should be monitored, particularly in patients with advanced CKD
- Risk of vitamin deficiency — sevelamer may reduce absorption of fat-soluble vitamins A, D, E, and K, and of folic acid. Vitamin and mineral supplementation may be required, particularly in dialysis patients on restricted diets
- Dialysis-related peritonitis — cases have been reported in peritoneal dialysis patients; prompt evaluation is required for abdominal pain or cloudy dialysate
Post-marketing reports include ileus, intestinal obstruction, intestinal perforation, fecal impaction, and gastrointestinal bleeding — some fatal. Stop taking sevelamer and seek urgent medical attention if you experience severe abdominal pain, persistent vomiting, inability to pass stool or gas, or bloody/black stools.
Monitoring During Treatment
Your healthcare team will regularly monitor several parameters while you are taking sevelamer carbonate:
- Serum phosphate — usually every 1–3 months, targeting levels toward the normal range (0.81–1.45 mmol/L; 2.5–4.5 mg/dL)
- Serum calcium — to ensure calcium balance is maintained
- Serum bicarbonate (HCO3−) — to detect metabolic acidosis
- Intact parathyroid hormone (iPTH) — to assess bone and mineral metabolism
- Vitamin D (25-OH vitamin D) and folate — periodically, especially in long-term users
Pregnancy and Breastfeeding
Animal studies suggest that sevelamer may reduce the absorption of fat-soluble vitamins, which could affect fetal development when vitamin intake is already marginal. There is limited data on the use of sevelamer carbonate in pregnant women. It should be used only if clearly necessary and after a careful risk-benefit assessment by your doctor. Women who become pregnant while taking sevelamer should inform their healthcare provider promptly.
It is not known whether sevelamer is excreted in human breast milk. Because sevelamer is not absorbed systemically, exposure of the breastfed infant is expected to be minimal; however, a decision should be made in consultation with a nephrologist whether to discontinue breastfeeding or sevelamer, taking into account the benefit of therapy for the mother.
Children and Adolescents
The safety and efficacy of Sevelamer carbonate Winthrop 800 mg tablets in children and adolescents under 6 years of age or under 75 cm in height have not been established. Pediatric formulations (powder for oral suspension) may be more appropriate for younger children; dosing should follow the reference paediatric product information and the advice of a paediatric nephrologist.
Driving and Operating Machinery
Sevelamer has no known effect on the ability to drive or operate machinery. However, if you feel unwell due to underlying kidney disease, electrolyte disturbances, or side effects such as dizziness, you should avoid driving until you feel better.
Sevelamer carbonate Winthrop tablets contain ingredients that may occasionally cause hypersensitivity in susceptible individuals. Always inform your pharmacist about previously known intolerances to medicine excipients.
How Does Sevelamer carbonate Winthrop Interact with Other Drugs?
Sevelamer can reduce the gut absorption of several medicines, including ciprofloxacin, levothyroxine, immunosuppressants (tacrolimus, cyclosporine, mycophenolate), and some antiarrhythmics and antiepileptics. As a general rule, take any interacting medicine at least 1 hour before or 3 hours after sevelamer, and monitor clinical response or blood levels where appropriate.
Because sevelamer is a bulky polymer that sits in the gastrointestinal tract, it can physically bind or delay the absorption of co-administered drugs. This effect is not mediated by cytochrome P450 or the liver, but by local intestinal interactions. Careful attention to timing is usually sufficient to manage these interactions without stopping either medication.
Major Interactions
| Interacting Drug/Class | Effect | Recommendation |
|---|---|---|
| Ciprofloxacin | Bioavailability reduced by approximately 50% when co-administered | Take ciprofloxacin at least 1 hour before or 3 hours after sevelamer |
| Levothyroxine | Decreased absorption leading to elevated TSH and hypothyroid symptoms | Separate administration; monitor TSH more closely after initiation |
| Cyclosporine, tacrolimus, mycophenolate | Decreased trough levels reported in transplant patients; risk of rejection | Monitor immunosuppressant levels; separate dosing; adjust dose as required |
| Antiarrhythmics (e.g. amiodarone, digoxin) | Theoretical reduction in absorption; narrow therapeutic index drugs | Take at least 1 hour before or 3 hours after sevelamer; monitor levels |
| Antiepileptics (e.g. phenytoin, carbamazepine) | Potential decreased absorption; risk of breakthrough seizures | Separate administration; monitor plasma levels and seizure control |
| Proton pump inhibitors (omeprazole, pantoprazole) | Altered gastric pH may theoretically affect sevelamer binding capacity | Monitor serum phosphate; adjust sevelamer dose if control worsens |
| Fat-soluble vitamins A, D, E, K and folate | Reduced intestinal absorption, potential deficiency with long-term use | Consider periodic monitoring and supplementation as indicated |
Minor and Theoretical Interactions
Sevelamer does not affect digoxin pharmacokinetics in a clinically meaningful way in most studies, and no significant interaction has been observed with warfarin in formal studies. Nevertheless, because warfarin has a narrow therapeutic index, INR should be monitored when sevelamer is initiated or stopped. Oral contraceptives have been shown to maintain adequate absorption when separated by at least 2 hours from sevelamer, but patients should discuss alternative or backup contraception with their healthcare provider if any doubt exists.
Rule of Thumb for Timing
For any medicine with a narrow therapeutic window, or any drug critical to ongoing therapy (immunosuppressants, levothyroxine, antibiotics, antiepileptics, antiarrhythmics), administer at least 1 hour before or 3 hours after sevelamer. Always ask your pharmacist when starting new medicines, including over-the-counter products, herbal remedies, and supplements.
What Is the Correct Dosage of Sevelamer carbonate Winthrop?
The usual starting dose for adults is 2.4 g to 4.8 g per day (one or two 800 mg tablets three times daily with meals), depending on serum phosphate and whether the patient has previously used a phosphate binder. The dose is titrated every 2–4 weeks to achieve a target serum phosphate of 1.78 mmol/L (5.5 mg/dL) or lower.
Dosing of sevelamer carbonate is individualised. Your nephrologist will set the starting dose based on your current serum phosphate level and adjust the dose over time based on regular blood tests. Sevelamer carbonate tablets are always taken with food — phosphate binders that are taken away from meals do not capture dietary phosphate effectively.
Adults: Starting Dose Based on Serum Phosphate
| Serum Phosphate | Starting Dose per Meal | Total Daily Dose |
|---|---|---|
| 1.78–2.42 mmol/L (5.5–7.5 mg/dL) | 800 mg (1 tablet) three times daily | 2.4 g |
| 2.42–2.91 mmol/L (7.5–9.0 mg/dL) | 1,600 mg (2 tablets) three times daily | 4.8 g |
| > 2.91 mmol/L (9.0 mg/dL) | 1,600 mg (2 tablets) three times daily | 4.8 g, titrate upwards |
Switching from Calcium Acetate or Other Binders
If you are switching from calcium acetate (667 mg) to sevelamer carbonate, use approximately the same number of tablets per meal (1 tablet of calcium acetate 667 mg ≈ 1 tablet of sevelamer carbonate 800 mg). If you are switching from sevelamer hydrochloride to sevelamer carbonate, the dose (in grams) is the same, as both salts contain the same polymer at the same molar concentration.
Dose Titration
Titration Principle
Serum phosphate should be measured every 2 to 4 weeks until a stable target level is reached. The daily dose can be adjusted in increments of 800 mg (1 tablet) per meal (an increase or decrease of 2.4 g/day). Most patients require a total daily dose of 6–7 g to achieve adequate phosphate control.
How to Take the Tablets
Administration Instructions
Swallow each tablet whole with water at the start of the meal or together with the first bites of food. Do not crush, chew, break, or split the tablets. If you are taking more than one tablet per meal, take them at approximately the same time with that meal. If you forget a dose, skip it and take your next dose with your next meal as usual — do not double-dose to make up for a missed dose.
Adults
The standard adult dose ranges from 2.4 g to 14 g per day, divided into three doses taken with meals. Most adults on dialysis require approximately 6–7 g per day (7–9 tablets), although this varies with dietary phosphate intake and residual renal function. The maximum studied daily dose is 14 g (about 18 tablets), which is rarely needed.
Children
Sevelamer carbonate Winthrop 800 mg tablets are not recommended in children below the age of 6 years or below 75 cm in height. In older children and adolescents, dosing is weight- or body-surface-area based. A paediatric powder formulation may be more appropriate for smaller children; treatment should be supervised by a paediatric nephrologist.
Elderly
No specific dose adjustment is required for elderly patients based on age alone. However, elderly patients are more likely to have reduced gastrointestinal motility, swallowing difficulties, or concomitant medications with narrow therapeutic windows. Start at the lower end of the dosing range and titrate carefully.
Patients on Dialysis
Both hemodialysis and peritoneal dialysis patients may use sevelamer carbonate. Dialysis removes only a limited amount of phosphate per session, so dietary phosphate restriction and phosphate binders remain cornerstones of long-term management. Sevelamer is taken during meals on both dialysis days and non-dialysis days.
Missed Dose
If you miss a dose, skip the missed dose and take your next dose at the usual time with your next meal. Do not take a double dose to compensate. Taking sevelamer without food will not effectively lower phosphate absorption.
Overdose
Sevelamer is not absorbed from the gastrointestinal tract, so systemic overdose is extremely unlikely. Very large doses have been tolerated in clinical trials (up to 14 g per day for 8 days) without systemic adverse effects. However, a single very large intake may cause constipation, abdominal distension, nausea, or bowel obstruction. If you or someone else has taken substantially more than prescribed, contact your nearest emergency department or a poison information centre for guidance. Supportive and symptomatic treatment is the mainstay; sevelamer is not removed by dialysis because it is not in the bloodstream.
What Are the Side Effects of Sevelamer carbonate Winthrop?
The most common side effects of sevelamer carbonate are gastrointestinal: nausea, vomiting, upper abdominal pain, constipation, diarrhea, indigestion, and flatulence. Serious but rare reactions include bowel obstruction, intestinal perforation, gastrointestinal bleeding, and hypersensitivity reactions. Report any severe abdominal symptoms to your doctor immediately.
Like all medicines, Sevelamer carbonate Winthrop can cause side effects, although not everybody gets them. Because the drug works locally in the gut, the most frequent side effects are gastrointestinal. Most are mild to moderate and often improve after the first few weeks of treatment or after a small dose adjustment.
Contact your doctor or emergency services immediately if you experience: severe or persistent abdominal pain, inability to pass stool or gas, persistent vomiting, black tarry stools or blood in stool, signs of an allergic reaction (swelling of face/tongue/throat, difficulty breathing, widespread rash or hives). These may represent bowel obstruction, perforation, gastrointestinal bleeding, or anaphylaxis.
Frequency Categories
Very Common (affects more than 1 in 10 patients)
- Nausea
- Vomiting
- Upper abdominal pain
- Constipation
Common (affects up to 1 in 10 patients)
- Diarrhea
- Indigestion (dyspepsia)
- Flatulence (gas)
- Lower abdominal pain
Uncommon (affects up to 1 in 100 patients)
- Pruritus (itching)
- Rash
- Metabolic acidosis
Very Rare / Post-Marketing Reports
- Hypersensitivity reactions including angioedema
- Intestinal obstruction, ileus, subileus
- Intestinal perforation
- Gastrointestinal bleeding
- Fecal impaction
- Intestinal crystal deposits (sevelamer-associated enterocolitis)
- Diverticulitis
Gastrointestinal Effects in Detail
Gastrointestinal symptoms are the hallmark side effect profile of sevelamer. Constipation is particularly common, especially in patients who are already prone to constipation due to dialysis, reduced mobility, or opioid analgesics. Adequate fluid intake (within any fluid restrictions prescribed by your nephrologist), appropriate dietary fibre, and timely treatment with a laxative or stool softener can usually keep constipation manageable. Nausea and upper abdominal pain often improve after the first 1–2 weeks. Taking the tablets at the start of the meal rather than at the end may help.
In rare but serious cases, sevelamer has been associated with intestinal crystal deposits seen on biopsy, sometimes presenting as ulcerations or colitis. This phenomenon, sometimes called "sevelamer-associated enterocolitis," is most often reported in patients with pre-existing mucosal disease or severe constipation. Any unexplained rectal bleeding, persistent diarrhea, or severe abdominal pain warrants prompt evaluation.
Metabolic and Vitamin-Related Effects
Long-term sevelamer use may lower serum bicarbonate, especially in patients on peritoneal dialysis. Modest metabolic acidosis is usually asymptomatic but may be treated with oral sodium bicarbonate or adjustment of dialysate composition. Sevelamer may also reduce absorption of vitamins A, D, E, K, and folic acid; periodic measurement and, if needed, supplementation are recommended in long-term users.
Hypersensitivity Reactions
Although uncommon, allergic reactions to sevelamer or its excipients can occur. Symptoms include skin rash, itching, swelling of the face, lips, tongue, or throat, and difficulty breathing. Stop taking sevelamer and seek medical attention immediately if any of these occur.
Reporting of Side Effects
If you experience any side effect, including any not listed in this article, talk to your doctor or pharmacist. You can also help improve the safety information of this medicine by reporting side effects directly via your national pharmacovigilance system (e.g. the EMA EudraVigilance system in the EU, the FDA MedWatch system in the US, or the MHRA Yellow Card Scheme in the UK).
How Should You Store Sevelamer carbonate Winthrop?
Store Sevelamer carbonate Winthrop 800 mg tablets below 25 °C (77 °F) in the original container to protect from moisture. Keep out of the sight and reach of children. Do not use after the expiry date printed on the carton and bottle, and dispose of unused tablets via a pharmacy take-back scheme — never in household waste water.
Safe storage protects both the integrity of the medicine and the safety of others in your household. The specific storage requirements for Sevelamer carbonate Winthrop 800 mg film-coated tablets are straightforward and do not require refrigeration.
Storage Conditions
- Temperature: Store below 25 °C (77 °F). Do not freeze
- Container: Keep the tablets in the original bottle tightly closed, to protect against moisture
- Location: A cool, dry cupboard away from direct sunlight, heat sources, and bathroom humidity is ideal
- Child safety: Keep the bottle out of sight and reach of children. Phosphate binders are prescription medicines and should be treated as such
Expiry Date
Check the expiry date printed on the carton and on the bottle label. The expiry date refers to the last day of that month. Do not take tablets that are past their expiry date, that appear damaged or discoloured, or that come from a container whose integrity is compromised (e.g. broken seal, moisture inside).
Disposal
Do not dispose of unused or expired medicines in wastewater or household waste. Return unused tablets to your pharmacy, which can arrange safe destruction according to local environmental regulations. These measures help protect waterways and reduce the environmental footprint of medicines.
When travelling, keep sevelamer carbonate tablets in their original container in your hand luggage. Avoid placing them in checked baggage where temperatures may exceed 25 °C. If travelling across time zones, coordinate dosing with meals in the new time zone rather than strictly by the clock.
What Does Sevelamer carbonate Winthrop Contain?
Each film-coated tablet contains 800 mg of the active substance sevelamer carbonate. The tablet core contains microcrystalline cellulose, sodium chloride, and zinc stearate; the film coating is hypromellose and diacetylated monoglycerides, with printing ink containing iron oxide, propylene glycol, and hypromellose.
Understanding what is inside your medicine is important, especially if you have dietary restrictions, are sensitive to certain excipients, or are monitoring your salt intake. The exact composition may vary slightly between manufacturers of sevelamer carbonate.
Active Substance
- Sevelamer carbonate — 800 mg per film-coated tablet
Sevelamer carbonate is a cross-linked poly(allylamine) polymer in which a portion of the free amine groups are protonated and paired with carbonate counterions. It is a white to off-white amorphous powder that does not dissolve in water but swells to form a hydrogel when wet, which provides the surface area needed to trap dietary phosphate.
Excipients (Inactive Ingredients)
Tablet core
- Microcrystalline cellulose — binder and bulking agent
- Sodium chloride — processing aid
- Zinc stearate (or magnesium stearate, depending on the batch) — lubricant
Film coating
- Hypromellose (HPMC) — film-forming polymer
- Diacetylated monoglycerides — plasticiser
Printing ink
- Iron oxide black (E172) — colourant
- Propylene glycol — solvent
- Hypromellose — binder
Sodium and Metabolic Considerations
Although sodium chloride is listed as an excipient, the quantity per tablet is negligible compared with dietary sodium intake and does not contribute meaningfully to sodium load. Sevelamer carbonate is considered "essentially sodium-free" per EU excipient guidelines.
Appearance and Packaging
Sevelamer carbonate Winthrop 800 mg tablets are oval, off-white, film-coated tablets debossed with the product identifier on one side. They are supplied in HDPE bottles containing 30, 60, 90, 180 (1 × 180), or 180 (2 × 90) tablets, depending on the market. Not all pack sizes may be marketed in every country.
Frequently Asked Questions About Sevelamer carbonate Winthrop
Sevelamer carbonate Winthrop is used to control high blood phosphate levels (hyperphosphatemia) in adults with chronic kidney disease. It is prescribed for adults receiving hemodialysis or peritoneal dialysis, and for adults with CKD not on dialysis whose serum phosphate is 1.78 mmol/L (5.5 mg/dL) or above. The medicine is taken with meals and binds phosphate from food inside the intestine so that less is absorbed into the bloodstream. This helps reduce the complications of CKD-mineral and bone disorder, including bone disease, secondary hyperparathyroidism, and vascular calcification.
Take Sevelamer carbonate Winthrop tablets whole with water, at the start of each meal. Do not crush, chew, break, or split the tablets. Typical dosing is one or two 800 mg tablets with each of the three main meals of the day, although your nephrologist will tailor the dose based on your serum phosphate level. The tablets must be taken with food to effectively bind dietary phosphate; taking them on an empty stomach will not produce the desired effect. If you forget a dose, skip it and resume with your next meal.
The most common side effects are gastrointestinal: nausea, vomiting, upper abdominal pain, and constipation occur in more than 1 in 10 patients. Diarrhea, indigestion, and flatulence are common. Most of these effects are mild to moderate and often improve after the first 1–2 weeks of treatment. Serious but uncommon events include intestinal obstruction, bowel perforation, and gastrointestinal bleeding. If you experience severe abdominal pain, inability to pass stool or gas, or blood in the stool, seek medical attention immediately.
No. Sevelamer carbonate is a non-calcium, non-aluminium, non-metallic phosphate binder. This distinguishes it from older agents such as calcium carbonate and calcium acetate, which can raise serum calcium and contribute to vascular calcification. KDIGO guidelines recommend restricting calcium-based phosphate binders in patients with CKD-MBD, making non-calcium binders such as sevelamer carbonate, lanthanum carbonate, and iron-based binders (sucroferric oxyhydroxide, ferric citrate) preferred options in many situations.
Sevelamer should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Because sevelamer can reduce the absorption of fat-soluble vitamins and folic acid, women who become pregnant while on sevelamer may require vitamin and folate supplementation to support fetal development. Sevelamer itself is not absorbed from the gut, so direct exposure of the fetus is expected to be minimal. Always inform your nephrologist and obstetrician if you are pregnant, planning to become pregnant, or breastfeeding.
Yes. Sevelamer can reduce the absorption of several medicines, including the antibiotic ciprofloxacin, the thyroid hormone levothyroxine, the immunosuppressants cyclosporine, tacrolimus, and mycophenolate mofetil, and certain antiarrhythmics and antiepileptics. As a general rule, take any interacting medicine at least 1 hour before or 3 hours after sevelamer. Your doctor may monitor blood levels or TSH more frequently when you start or stop sevelamer. Always tell your healthcare provider and pharmacist about all medications, supplements, and herbal products you take.
Calcium-based binders (calcium carbonate, calcium acetate) are effective but add calcium to the body, which may contribute to hypercalcemia and vascular calcification. Sevelamer is a non-absorbed polymer that does not add calcium, aluminium, or metals. It also modestly lowers LDL cholesterol by binding bile acids — an effect calcium-based binders do not share. Head-to-head studies such as the Treat-to-Goal and RIND trials suggest sevelamer may slow progression of coronary artery and aortic calcification compared with calcium binders in dialysis patients.
References
- European Medicines Agency (EMA). Sevelamer carbonate Zentiva (reference product for Sevelamer carbonate Winthrop) — European Public Assessment Report and Summary of Product Characteristics. Available at: ema.europa.eu/en/medicines/human/EPAR/sevelamer-carbonate-zentiva. Accessed December 2025.
- U.S. Food and Drug Administration (FDA). Renvela (sevelamer carbonate) — Prescribing Information. Approved 2007, updated 2024.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001
- Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62(1):245-252.
- Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients (RIND study). Kidney Int. 2007;71(5):438-441.
- Ruospo M, Palmer SC, Natale P, et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database of Systematic Reviews. 2018, Issue 8. Art. No.: CD006023.
- Palmer SC, Gardner S, Tonelli M, et al. Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials. Am J Kidney Dis. 2016;68(5):691-702.
- British National Formulary (BNF). Sevelamer carbonate monograph. London: BMJ Group and Pharmaceutical Press; updated 2025.
- National Institute for Health and Care Excellence (NICE). Chronic kidney disease: assessment and management (NG203). London: NICE; 2021.
- World Health Organization (WHO). International Classification of Diseases, 11th Revision (ICD-11) — Chronic kidney disease and mineral bone disorder.
About the Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialists in nephrology, clinical pharmacology, and internal medicine. Our content follows the GRADE evidence framework and is based on peer-reviewed research, international clinical guidelines (EMA, FDA, KDIGO, NICE), and established medical standards.
Every article undergoes a rigorous multi-step review: initial research by medical writers, clinical accuracy verification by specialist physicians, editorial review for clarity and accessibility, and final approval by the Medical Review Board.
We prioritise Level 1A evidence from systematic reviews and randomised controlled trials. All medical claims are referenced to peer-reviewed sources. No commercial funding influences our content.
Last medically reviewed: | Published: | Read our editorial standards